Will the NHS ever pay for the new era of dementia drugs?
Briefly

The decision on lecanemab's funding highlights the stark reality of balancing desperate patient needs against the necessary, cold, hard calculations of cost-effectiveness.
While Lecanemab was celebrated for being the first drug to demonstrate any effect on slowing Alzheimer's, it ultimately does not cure or halt the disease.
Read at www.bbc.com
[
|
]